Operating Income Summary of Novo Nordisk A/S

Novo Nordisk A/S's latest annual operating income in 2023 was 102.57 Billion DKK , up 37.11% from previous year.
Novo Nordisk A/S's latest quarterly operating income in 2024 Q2 was 25.52 Billion DKK , down -19.99% from previous quarter.
Novo Nordisk A/S reported an annual operating income of 74.8 Billion DKK in 2022, up 27.56% from previous year.
Novo Nordisk A/S reported an annual operating income of 58.64 Billion DKK in 2021, up 8.35% from previous year.
Novo Nordisk A/S reported a quarterly operating income of 32.41 Billion DKK for 2024 Q1, up 21.1% from previous quarter.
Novo Nordisk A/S reported a quarterly operating income of 26.76 Billion DKK for 2023 Q4, down -0.55% from previous quarter.

Annual Operating Income Chart of Novo Nordisk A/S (2023 - 1989)

Historical Annual Operating Income of Novo Nordisk A/S (2023 - 1989)

Year	Operating Income	Operating Income Growth
2023	102.57 Billion DKK	37.11%
2022	74.8 Billion DKK	27.56%
2021	58.64 Billion DKK	8.35%
2020	54.12 Billion DKK	3.13%
2019	52.48 Billion DKK	11.08%
2018	47.24 Billion DKK	-3.51%
2017	48.96 Billion DKK	1.1%
2016	48.43 Billion DKK	-2.05%
2015	49.44 Billion DKK	43.35%
2014	34.49 Billion DKK	9.52%
2013	31.49 Billion DKK	6.85%
2012	29.47 Billion DKK	31.73%
2011	22.37 Billion DKK	18.44%
2010	18.89 Billion DKK	26.51%
2009	14.93 Billion DKK	20.38%
2008	12.4 Billion DKK	38.53%
2007	8.95 Billion DKK	-1.81%
2006	9.12 Billion DKK	12.94%
2005	8.07 Billion DKK	14.87%
2004	7.02 Billion DKK	9.78%
2003	6.4 Billion DKK	7.2%
2002	5.97 Billion DKK	6.72%
2001	5.59 Billion DKK	31.91%
2000	4.24 Billion DKK	17.37%
1999	3.61 Billion DKK	74.92%
1998	2.06 Billion DKK	-11.46%
1997	2.33 Billion DKK	17.88%
1996	1.98 Billion DKK	5.74%
1995	1.87 Billion DKK	1.77%
1994	1.84 Billion DKK	-5.35%
1993	1.94 Billion DKK	67.8%
1992	1.15 Billion DKK	-17.48%
1991	1.4 Billion DKK	33.4%
1990	1.05 Billion DKK	0.23%
1989	1.04 Billion DKK	12.14%

Year	Operating Income	Operating Income Growth
2024 Q2	25.52 Billion DKK	-19.99%
2024 Q1	32.41 Billion DKK	21.1%
2023 Q4	26.76 Billion DKK	-0.55%
2023 Q1	25 Billion DKK	202.05%
2023 FY	102.57 Billion DKK	37.11%
2023 Q3	26.91 Billion DKK	12.66%
2023 Q2	23.88 Billion DKK	-4.47%
2022 Q1	19.14 Billion DKK	40.44%
2022 Q4	8.27 Billion DKK	-58.98%
2022 Q3	20.18 Billion DKK	9.75%
2022 FY	74.8 Billion DKK	27.56%
2022 Q2	18.39 Billion DKK	-3.95%
2021 Q1	14.98 Billion DKK	34.03%
2021 Q4	13.63 Billion DKK	-10.59%
2021 Q3	15.24 Billion DKK	3.18%
2021 Q2	14.77 Billion DKK	-1.35%
2021 FY	58.64 Billion DKK	8.35%
2020 Q2	13.83 Billion DKK	-15.11%
2020 Q1	16.3 Billion DKK	37.3%
2020 FY	54.12 Billion DKK	3.13%
2020 Q4	11.17 Billion DKK	-12.73%
2020 Q3	12.8 Billion DKK	-7.44%
2019 Q3	12.91 Billion DKK	-3.96%
2019 Q1	14.23 Billion DKK	32.05%
2019 Q2	13.45 Billion DKK	-5.53%
2019 Q4	11.87 Billion DKK	-8.1%
2019 FY	52.48 Billion DKK	11.08%
2018 Q4	10.78 Billion DKK	-8.72%
2018 Q3	11.81 Billion DKK	-3.2%
2018 Q2	12.2 Billion DKK	-1.96%
2018 Q1	12.44 Billion DKK	23.9%
2018 FY	47.24 Billion DKK	-3.51%
2017 FY	48.96 Billion DKK	1.1%
2017 Q4	10.04 Billion DKK	-16.58%
2017 Q3	12.04 Billion DKK	-10.03%
2017 Q2	13.38 Billion DKK	-0.77%
2017 Q1	13.49 Billion DKK	20.38%
2016 Q2	12.49 Billion DKK	1.53%
2016 Q1	12.3 Billion DKK	10.64%
2016 FY	48.43 Billion DKK	-2.05%
2016 Q3	12.42 Billion DKK	-0.62%
2016 Q4	11.2 Billion DKK	-9.77%
2015 FY	49.44 Billion DKK	43.35%
2015 Q3	11.98 Billion DKK	-4.02%
2015 Q1	13.85 Billion DKK	51.33%
2015 Q4	11.12 Billion DKK	-7.14%
2015 Q2	12.48 Billion DKK	-9.92%
2014 Q1	8.03 Billion DKK	9.23%
2014 FY	34.49 Billion DKK	9.52%
2014 Q4	9.15 Billion DKK	6.86%
2014 Q3	8.56 Billion DKK	-1.88%
2014 Q2	8.73 Billion DKK	8.71%
2013 FY	31.49 Billion DKK	6.85%
2013 Q3	7.99 Billion DKK	-6.91%
2013 Q1	7.56 Billion DKK	-0.13%
2013 Q2	8.58 Billion DKK	13.53%
2013 Q4	7.35 Billion DKK	-7.98%
2012 FY	29.47 Billion DKK	31.73%
2012 Q3	7.86 Billion DKK	2.76%
2012 Q2	7.65 Billion DKK	19.86%
2012 Q1	6.38 Billion DKK	5.0%
2012 Q4	7.57 Billion DKK	-3.71%
2011 Q3	5.61 Billion DKK	6.55%
2011 FY	22.37 Billion DKK	18.44%
2011 Q4	6.08 Billion DKK	8.4%
2011 Q2	5.26 Billion DKK	-2.82%
2011 Q1	5.41 Billion DKK	24.72%
2010 Q2	5.04 Billion DKK	15.04%
2010 Q1	4.38 Billion DKK	36.13%
2010 Q4	4.34 Billion DKK	-15.22%
2010 FY	18.89 Billion DKK	26.51%
2010 Q3	5.12 Billion DKK	1.65%
2009 Q4	3.21 Billion DKK	-15.6%
2009 FY	14.93 Billion DKK	20.38%
2009 Q2	4.09 Billion DKK	7.35%
2009 Q1	3.81 Billion DKK	11.62%
2009 Q3	3.81 Billion DKK	-6.75%
2008 FY	12.4 Billion DKK	38.53%
2008 Q2	2.84 Billion DKK	0.71%
2008 Q3	3.32 Billion DKK	16.57%
2008 Q4	3.41 Billion DKK	2.8%
2008 Q1	2.82 Billion DKK	147.9%
2007 FY	8.95 Billion DKK	-1.81%
2007 Q2	2.81 Billion DKK	20.78%
2007 Q3	2.67 Billion DKK	-4.68%
2007 Q4	1.14 Billion DKK	-57.42%
2007 Q1	2.32 Billion DKK	10.67%
2006 Q3	2.5 Billion DKK	-4.82%
2006 Q2	2.63 Billion DKK	39.76%
2006 FY	9.12 Billion DKK	12.94%
2006 Q4	2.1 Billion DKK	-16.08%
2006 Q1	1.88 Billion DKK	-1.67%
2005 Q1	1.51 Billion DKK	-17.65%
2005 FY	8.07 Billion DKK	14.87%
2005 Q4	1.91 Billion DKK	-16.98%
2005 Q3	2.3 Billion DKK	-1.33%
2005 Q2	2.33 Billion DKK	54.72%
2004 Q3	1.77 Billion DKK	3.45%
2004 FY	7.02 Billion DKK	9.78%
2004 Q4	1.83 Billion DKK	3.62%
2004 Q2	1.71 Billion DKK	13.81%
2004 Q1	1.5 Billion DKK	-17.5%
2003 Q1	1.31 Billion DKK	110.55%
2003 Q4	1.82 Billion DKK	11.4%
2003 Q3	1.63 Billion DKK	1.81%
2003 Q2	1.6 Billion DKK	21.93%
2003 FY	6.4 Billion DKK	7.2%
2002 FY	5.97 Billion DKK	6.72%
2002 Q2	5.27 Billion DKK	-12.32%
2002 Q1	6.02 Billion DKK	151.82%
2002 Q3	6.44 Billion DKK	22.11%
2002 Q4	-12.49 Billion DKK	-293.91%
2001 Q2	5.74 Billion DKK	7.47%
2001 Q1	5.34 Billion DKK	137.11%
2001 FY	5.59 Billion DKK	31.91%
2001 Q4	-11.61 Billion DKK	-274.63%
2001 Q3	6.65 Billion DKK	15.78%
2000 Q4	-14.4 Billion DKK	-193.88%
2000 FY	4.24 Billion DKK	17.37%
2000 Q3	15.34 Billion DKK	136.62%
2000 Q2	6.48 Billion DKK	16.57%
2000 Q1	5.56 Billion DKK	147.28%
1999 Q1	4.63 Billion DKK	142.23%
1999 FY	3.61 Billion DKK	74.92%
1999 Q4	-11.76 Billion DKK	-302.07%
1999 Q3	5.82 Billion DKK	15.94%
1999 Q2	5.02 Billion DKK	8.45%
1998 FY	2.06 Billion DKK	-11.46%
1998 Q2	4.56 Billion DKK	8.95%
1998 Q1	4.19 Billion DKK	142.09%
1998 Q3	5.03 Billion DKK	10.22%
1998 Q4	-10.96 Billion DKK	-317.84%
1997 Q3	4.31 Billion DKK	4.63%
1997 FY	2.33 Billion DKK	17.88%
1997 Q1	3.62 Billion DKK	141.58%
1997 Q2	4.12 Billion DKK	13.72%
1997 Q4	-9.96 Billion DKK	-330.83%
1996 FY	1.98 Billion DKK	5.74%
1996 Q4	-8.72 Billion DKK	-337.73%
1996 Q3	3.66 Billion DKK	4.6%
1996 Q2	3.5 Billion DKK	2.12%
1996 Q1	3.43 Billion DKK	140.75%
1995 Q2	3.57 Billion DKK	6.01%
1995 Q1	3.37 Billion DKK	141.51%
1995 Q3	3.21 Billion DKK	-9.94%
1995 FY	1.87 Billion DKK	1.77%
1995 Q4	-8.42 Billion DKK	-361.95%
1994 FY	1.84 Billion DKK	-5.35%
1994 Q1	3.11 Billion DKK	144.7%
1994 Q2	3.42 Billion DKK	10.02%
1994 Q3	3.37 Billion DKK	-1.4%
1994 Q4	-8.12 Billion DKK	-340.61%
1993 Q4	-6.96 Billion DKK	-322.29%
1993 Q1	2.62 Billion DKK	138.63%
1993 Q2	3 Billion DKK	14.37%
1993 Q3	3.13 Billion DKK	4.25%
1993 FY	1.94 Billion DKK	67.8%
1992 Q3	2.56 Billion DKK	-8.67%
1992 Q4	-6.79 Billion DKK	-364.96%
1992 Q2	2.8 Billion DKK	5.54%
1992 FY	1.15 Billion DKK	-17.48%
1992 Q1	2.66 Billion DKK	148.56%
1991 Q1	2.27 Billion DKK	145.95%
1991 Q2	2.24 Billion DKK	-1.2%
1991 FY	1.4 Billion DKK	33.4%
1991 Q4	-5.48 Billion DKK	-329.06%
1991 Q3	2.39 Billion DKK	6.4%
1990 Q1	1.94 Billion DKK	143.86%
1990 Q3	2.02 Billion DKK	-0.11%
1990 FY	1.05 Billion DKK	0.23%
1990 Q4	-4.95 Billion DKK	-344.08%
1990 Q2	2.03 Billion DKK	4.7%
1989 Q3	1.74 Billion DKK	-0.53%
1989 Q1	1.97 Billion DKK	164.62%
1989 FY	1.04 Billion DKK	12.14%
1989 Q4	-4.42 Billion DKK	-353.14%
1989 Q2	1.75 Billion DKK	-11.07%

Peer Operating Income Comparison of Novo Nordisk A/S

Name	Operating Income	Operating Income Difference
ADC Therapeutics SA	-165.98 Million USD	61896.778%
Alto Neuroscience, Inc.	-37.8 Million USD	271395.194%
Annovis Bio, Inc.	-45.03 Million USD	227865.016%
Biohaven Pharmaceutical Holding Company Ltd.	-436.05 Million USD	23623.395%
Ginkgo Bioworks Holdings, Inc.	-864.4 Million USD	11966.415%
Nuvation Bio Inc.	-99.82 Million USD	102856.907%
Nuvation Bio Inc.	-99.82 Million USD	102856.907%
Arcus Biosciences, Inc.	-340 Million USD	30268.824%
Theriva Biologics, Inc.	-21.43 Million USD	478724.423%
Zymeworks Inc.	-138.05 Million USD	74400.45%

Global Stocks Search

Novo Nordisk A/S (NVO)

Operating Income Summary of Novo Nordisk A/S

Annual Operating Income Chart of Novo Nordisk A/S (2023 - 1989)

Historical Annual Operating Income of Novo Nordisk A/S (2023 - 1989)

Peer Operating Income Comparison of Novo Nordisk A/S